

## Abbreviated Trigger Diagnosis by ICD-9 and ICD-10 (04.17)

Diagnosis/General Description	ICD-9	ICD-10
<b>Organ and Tissue Transplants</b>		
transplants, implants, etc.	V42.0–V59	Z94 - Z969
complications of organ transplant	996.80–996.89	T8600 - T8699
<b>Neoplasms – if \$100,000 or more</b>		
malignancies	140.0–198.9	C000 - C7989 / D030 - D0399
hematopoietic cancers	200.0–208.92	C81 - C96
neuroendocrine tumors – malignant	209.0-209.3	C7A00 - C7A098
cancer with prolonged hospital stay	230.0–239.9	D00 - D499 / C9440 - C9442 / Q8500 - Q8509
<b>Endocrine and Metabolic Diseases</b>		
Gaucher’s disease, Fabry’s disease, etc.	272.7	E7521 and E7522
<b>Diseases of the Blood and Blood-Forming Organs</b>		
aplastic anemia	284.0–284.9	D600 - D619
<b>Diseases of the Genitourinary System</b>		
renal dialysis	V45.1	Z992 & Z9115
acute renal failure	584	N170 - N179
chronic renal failure	585	N181 - N189
<b>Congenital Anomalies</b>		
spina bifida	741	Q050 - Q058 / Q0701 - Q0703
congenital anomaly of nervous system	742	Q02 - Q048
congenital anomaly of ear, face, neck	744	Q169 - Q189
cardiac congenital and valve disorders	745–747.9	Q200 - Q289
respiratory system anomaly	748	Q300 - Q349
congenital anomaly of digestive system	750.3–751.9	Q381 - Q459
chromosomal anomaly	758	Q909 - Q999
other unspecified congenital anomaly	759.9	Q899
<b>In addition</b>		
<ul style="list-style-type: none"> <li>▪ Any diagnosis resulting in extended inpatient confinements greater than 30 days</li> <li>▪ Any diagnosis with \$500,000 or more in cumulative payments</li> <li>▪ Costly services or medications extended inpatient confinements greater than 30 days</li> </ul>		
<b>Specialty Pharmaceuticals</b>		

<b>Diagnosis/General Description</b>	<b>ICD-9</b>	<b>ICD-10</b>	<b>Drug</b>	<b>J Code</b>
Malignant melanoma	172.0	C43	Yervoy® (Ipilimumab) Keytruda® Mekinist® Tafinlar® Zelboraf® Opvido®	J9228 J9999
Pompe's Disease	271.00	E74.02	Myozyme® (alglucosidase alfa) Lumizyme® (alglucosidase alfa)	J0220 J0221
Lipidoses (Fabry's disease)	272.70	E75.21 & 272.7	Fabrazyme® (agalsidase beta)	J0180
Mucopolysaccharidosis (Maroteaux-Lamy syndrome)	277.50	E76.0	Naglazyme® (galsulfase)	J1458
Mucopolysaccharidosis (unspecified)		E76.6	Naglazyme® (galsulfase)	
Mucopolysaccharidosis (Hunter's syndrome)	277.50	E76.3	Elaprased® (idursulfase)	J1743
Cystic Fibrosis	277.00	E84	Kalydeco™ (ivacaftor) Pulmozyme® Cayston® Tobi® Tobramycin	
Hereditary angioedema	277.60	D84.1	Cinryze® (C1 esterase inhibitor) Ruconest® Berinert® Firazyr®	J0598
Atypical hemolytic uremic syndrome	283.11	D59.3	Soliris® (eculizumab)	J1300
Factor VIII deficiency	286.0	D66	Novoseven®	J7189
Factor IX deficiency	286.1	D67	BeneFIX® - recombinant	J3195
Congenital factor XI disorder (hemophilia C)	286.2		Alprolix®	J7201
Congenital deficiency of other clotting factory	286.3		BeneFIX® - recombinant	J3195
Congenital deficiency of other clotting factory	286.5		Novoseven®	J7189
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.6			
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.7			
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.9			
Defibrination syndrome				
Acquired coagulation deficiency				
Other and unspecified coagulation defects				
Von Willebrand's disease	286.4	D68	Alphanate® - plasma	J7186

			Humate® P - plasma	J7187
Factor VIII deficiency	286.0	D66	Hemofil M® - plasma Koate®-DVI – plasma Monoclata-P® - plasma	J7190
Congenital factor XI disorder (hemophilia C)	286.2			
Congenital deficiency of other clotting factory	286.3			
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.5			
Defibrination syndrome	286.6			
Acquired coagulation deficiency	286.7			
Other and unspecified coagulation defects	286.9			
Factor VIII deficiency	286.0	<b>D66</b>	Advate® - recombinant Helixate®FS - recombinant Kogenate® - recombinant Recombinate® - recombinant ReFacto® - recombinant Elocate® - recombinant Obizur® - recombinant	J7192
Congenital factor XI disorder (hemophilia C)	286.2			J7199
Congenital deficiency of other clotting factory	286.3			
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.5			
Defibrination syndrome	286.6			
Acquired coagulation deficiency	286.7			
Other and unspecified coagulation defects	286.9			
Factor IX deficiency	286.1	<b>D67</b>	AlphaNine® SD - plasma Mononine® - plasma	J7193
Congenital factor XI disorder (hemophilia C)	286.2			
Congenital deficiency of other clotting factory	286.3			
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.5			
Defibrination syndrome	286.6			
Acquired coagulation deficiency	286.7			
Other and unspecified coagulation defects	286.9			
Factor IX deficiency	286.1	<b>D67</b>	Bebulin® VH - plasma Profilnine® SD – plasma	J7194
Congenital factor XI disorder (hemophilia C)	286.2			
Congenital deficiency of other clotting factory	286.3			
Hemorrhagic disorder due to intrinsic circulating anticoagulants	286.5			
	286.6			

Defibrination syndrome Acquired coagulation deficiency Other and unspecified coagulation defects	286.7 286.9						
Paroxysmal nocturnal hemoglobinuria (Marchiafava-Micheli)	786.09	D59.5	Soliris® (eculizumab)	J1300			
<b>Specialty Pipeline Pharmaceuticals</b>							
<b>Drug Name</b>	<b>Disease Treated</b>	<b>ICD-10</b>	<b>Approx. Approval Date</b>	<b>Route of Admin</b>	<b>Projected Costs</b>	<b>Current Disease Treatment</b>	<b>Expected Financial Impact</b>
Zepatier (grazoprevir/elbasvir)	Chronic hepatitis Geno I & IV	K73 K73.8 K73.9 B17 B18.1 B19.2					
sofosbuvir / velpatasvir	Chronic Hepatitis	B17 B18.1 B19.2					
migalastat	Fabry disease	E75.21	2017	Oral	~\$300,000 per year (tent.)	First in class	HIGH
obeticholic acid	Primary biliary cirrhosis	K74.3	Feb. 29, 2016	Oral	~\$50,000 per year (tent.)	Actigall (replacement therapy)	Moderate
Achtar gel	Infantile seizures or spasms	F44.5 G40					